Naltrexone for Severe Self-Harm Behavior: A Case Report
Publication: American Journal of Psychiatry
To the Editor: Naltrexone is an opioid receptor antagonist approved by the Food and Drug Administration for alcohol and opioid dependence. Case reports have noted efficacy in impulse control disorders and self-injury, particularly in populations with developmental delay (1). Newer research suggests that response to naltrexone may be predicted by elevated beta-endorphin levels following self-injurious behavior (2). We report on a case of severe treatment-resistant self-mutilating behavior successfully treated with naltrexone.
“Ms. R” is a 32-year-old woman of normal intelligence with over 50 psychiatric hospitalizations in the past 8 years, most for cutting behavior deemed dangerous to self because of the quantity and severity of the wounds. She had a diagnosis of recurrent major depressive disorder superimposed on borderline personality disorder, with micro-psychotic episodes and poor impulse control. The patient had failed to benefit from multiple adequate trials with various combinations of antidepressants, atypical antipsychotics, conventional antipsychotics, mood stabilizers, benzodiazepines, alpha1 antagonists, intensive case management, and elements of dialectical behavioral therapy. We discussed with the patient the risks and the potential benefits of a trial of naltrexone to reduce her urges to cut. Liver function test results were mildly elevated from fatty liver secondary to metabolic syndrome. Other psychotropic medications were not changed. The patient was treated with naltrexone, 25 mg/day, titrated up to 50 mg after 1 month. Her medications were given by her home health nurses or her grandmother, and she was compliant with taking them.Ms. R noted decreased urges to cut after 1 week of treatment, with a reduced frequency of cutting behavior after her dosage was increased to 50 mg/day. The patient stated that she used to think about cutting “constantly” and would cut one to three times per day, but now will go “days” without thinking about it and only cut one to two times per week at most. After 5 months of continuous treatment, she had a 6-month period with only one superficial cutting episode. Liver function tests improved from baseline, with the exception of a 16-point increase in aspartate aminotransferase, which was stable over the course of several months.
This case highlights the potential efficacy of naltrexone in self-injurious behavior resistant to multiple psychopharmacological and behavioral interventions. Utilization of this treatment may allow for tapering or discontinuation of atypical antipsychotics and mood stabilizers that have significant metabolic side effects, including weight gain and diabetes. Although previous reports have described similar effects, the magnitude of the response, the medical comorbidities, and the resistance to treatment in this patient demonstrate a need to consider naltrexone sooner in treatment algorithms. Our group has also used naltrexone to treat an autistic man with sexually violent behavior and an elderly man with dementia and sexually inappropriate behavior, with resolution of symptoms and no adverse events. Large-scale randomized placebo-controlled trials are necessary to provide further evidence for the use of naltrexone in refractory cases of impulse control disorders.
Footnote
Accepted for publication in December 2010.
References
1.
Modesto-Lowe V, Van Kirk J: Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol 2002; 10:213–227
2.
Sandman CA, Touchette PE, Marion SD, Chicz-DeMet A: The role of proopiomelanocortin (POMC) in sequentially dependent self-injurious behavior. Dev Psychobiol 2008; 50:680–689
Information & Authors
Information
Published In
History
Accepted: December 2010
Published online: 1 April 2011
Published in print: April 2011
Authors
Funding Information
The authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).